

11-7-2022

## The NOGO Receptor NgR2, A Novel $\alpha V\beta 3$ Integrin Effector, Induces Neuroendocrine Differentiation in Prostate Cancer

Fabio Quaglia  
*Thomas Jefferson University*

Shiv Ram Krishn  
*Thomas Jefferson University*

Khalid Sossey-Alaoui  
*Case Western Reserve University*

Priyanka Shailendra Rana  
*Case Western Reserve University*

Follow this and additional works at: <https://jdc.jefferson.edu/cbfp>

Elzbieta Pluskota  
 [Open Access](#) Medical Pharmacology Commons, and the Oncology Commons

**[Let us know how access to this document benefits you](#)**

*See next page for additional authors*

### Recommended Citation

Quaglia, Fabio; Krishn, Shiv Ram; Sossey-Alaoui, Khalid; Rana, Priyanka Shailendra; Pluskota, Elzbieta; Park, Pyung Hun; Shields, Christopher D.; Lin, Stephen; McCue, Peter; Kossenkova, Andrew V.; Wang, Yanqing; Goodrich, David W.; Ku, Sheng-Yu; Beltran, Himisha; Kelly, William K.; Corey, Eva; Klose, Maja; Bandtlow, Christine; Liu, Qin; Altieri, Dario C.; Plow, Edward F.; and Languino, Lucia R., "The NOGO Receptor NgR2, A Novel  $\alpha V\beta 3$  Integrin Effector, Induces Neuroendocrine Differentiation in Prostate Cancer" (2022). *Department of Cancer Biology Faculty Papers*. Paper 196.  
<https://jdc.jefferson.edu/cbfp/196>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

## Authors

Fabio Quaglia, Shiv Ram Krishn, Khalid Sossey-Alaoui, Priyanka Shailendra Rana, Elzbieta Pluskota, Pyung Hun Park, Christopher D. Shields, Stephen Lin, Peter McCue, Andrew V. Kossenkov, Yanqing Wang, David W. Goodrich, Sheng-Yu Ku, Himisha Beltran, William K. Kelly, Eva Corey, Maja Klose, Christine Bandtlow, Qin Liu, Dario C. Altieri, Edward F. Plow, and Lucia R. Languino



OPEN

# The NOGO receptor NgR2, a novel $\alpha V\beta 3$ integrin effector, induces neuroendocrine differentiation in prostate cancer

Fabio Quaglia<sup>1,2</sup>, Shiv Ram Krishn<sup>1,2</sup>, Khalid Sossey-Alaoui<sup>3</sup>, Priyanka Shailendra Rana<sup>3</sup>, Elzbieta Pluskota<sup>4</sup>, Pyung Hun Park<sup>1,2</sup>, Christopher D. Shields<sup>1,2</sup>, Stephen Lin<sup>1,2</sup>, Peter McCue<sup>5</sup>, Andrew V. Kossenkov<sup>6</sup>, Yanqing Wang<sup>7</sup>, David W. Goodrich<sup>7</sup>, Sheng-Yu Ku<sup>8</sup>, Himisha Beltran<sup>8</sup>, William K. Kelly<sup>9</sup>, Eva Corey<sup>10</sup>, Maja Klose<sup>11</sup>, Christine Bandtlow<sup>11</sup>, Qin Liu<sup>12</sup>, Dario C. Altieri<sup>13</sup>, Edward F. Plow<sup>4</sup> & Lucia R. Languino<sup>1,2</sup>✉

Androgen deprivation therapies aimed to target prostate cancer (PrCa) are only partially successful given the occurrence of neuroendocrine PrCa (NEPrCa), a highly aggressive and highly metastatic form of PrCa, for which there is no effective therapeutic approach. Our group has demonstrated that while absent in prostate adenocarcinoma, the  $\alpha V\beta 3$  integrin expression is increased during PrCa progression toward NEPrCa. Here, we show a novel pathway activated by  $\alpha V\beta 3$  that promotes NE differentiation (NED). This novel pathway requires the expression of a GPI-linked surface molecule, NgR2, also known as Nogo-66 receptor homolog 1. We show here that NgR2 is upregulated by  $\alpha V\beta 3$ , to which it associates; we also show that it promotes NED and anchorage-independent growth, as well as a motile phenotype of PrCa cells. Given our observations that high levels of  $\alpha V\beta 3$  and, as shown here, of NgR2 are detected in human and mouse NEPrCa, our findings appear to be highly relevant to this aggressive and metastatic subtype of PrCa. This study is novel because NgR2 role has only minimally been investigated in cancer and has instead predominantly been analyzed in neurons. These data thus pave new avenues toward a comprehensive mechanistic understanding of integrin-directed signaling during PrCa progression toward a NE phenotype.

Integrins are transmembrane receptors composed of two non-covalently linked subunits ( $\alpha$  and  $\beta$ ) and, as indicated by various studies, show altered distribution during prostate cancer (PrCa) progression<sup>1–3</sup>. The  $\alpha V\beta 3$  integrin is usually present at low levels in normal human prostate cells but is highly expressed in advanced PrCa; it promotes invasion and adhesion of cancer cells to extracellular matrix proteins, such as vitronectin<sup>3,4</sup>. The activation state of the  $\alpha V\beta 3$  integrin, the affinity/avidity for cognate ligands, is regulated by Kindlin-2 (K2, Mig-2, *FERMT2*)<sup>5–7</sup>, which interacts with the cytoplasmic tail of the  $\beta 3$  subunit<sup>8–10</sup>. K2 is expressed in many different cell types and plays an essential role during integrin-dependent interaction between cells and the extracellular matrix<sup>11</sup>.

<sup>1</sup>Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA. <sup>2</sup>Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA. <sup>3</sup>Department of Medicine, School of Medicine, MetroHealth Medical Center, Rammelkamp Center for Research, Case Western Reserve University, Cleveland, OH, USA. <sup>4</sup>Cardiovascular and Metabolic Sciences Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. <sup>5</sup>Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA. <sup>6</sup>Center for Systems and Computational Biology, Wistar Institute, Philadelphia, PA, USA. <sup>7</sup>Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. <sup>8</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. <sup>9</sup>Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA. <sup>10</sup>Department of Urology, University of Washington, Seattle, WA, USA. <sup>11</sup>Institute of Neurochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. <sup>12</sup>Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA. <sup>13</sup>Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA. ✉email: lucia.languino@jefferson.edu

Recently, we have reported that the  $\alpha\text{V}\beta 3$  integrin is highly expressed in human and mouse neuroendocrine prostate cancer (NEPrCa) but absent in prostate adenocarcinoma (ADPrCa)<sup>12,13</sup>. In contrast, another  $\alpha\text{V}$  integrin,  $\alpha\text{V}\beta 6$ , is present in ADPrCa<sup>14</sup> but is negligible in NEPrCa<sup>13</sup>. NEPrCa is a highly aggressive and metastatic subtype of PrCa that typically develops from subsets of castrate-resistant PrCa (CRPrCa) cells<sup>15</sup>. NEPrCa develops either de novo or through the acquisition of alterations in pre-existing epithelial tumors in response to androgen deprivation therapies<sup>15–17</sup>. The NE phenotype appears to result from cells that do not express androgen receptor (AR) or prostate-specific antigen (PSA) but instead express neuron-specific proteins, such as synaptophysin (SYP), neuron-specific enolase (NSE), and chromogranin A (CHGA)<sup>18,19</sup>. These aberrations activate pro-tumorigenic pathways independently from those downstream of the AR<sup>20,21</sup>. A recent study suggests that other changes, in addition to AR signaling loss, are necessary for neuroendocrine differentiation (NED) to take place<sup>22</sup>. The role of the  $\alpha\text{V}\beta 3$  integrin in NEPrCa has not been investigated.

The Nogo receptor family is formed by three structurally related molecules: NgR1, NgR2, and NgR3. NgR2 core protein (45 kDa), in this study its sialylated form (48 kDa), or glycosylated forms (65 kDa) are predominantly detected<sup>23</sup>. NgRs are glycosylphosphatidylinositol (GPI)-anchored receptors that lack both the transmembrane and the intracellular domains<sup>24,25</sup>. This protein family is characterized by eight leucine-rich repeats (LRR) flanked by the N- and C-terminal cysteine-rich regions. The C-terminal LRR domain is connected to the GPI-anchor for the membrane attachment via a stalk region<sup>24,25</sup>. Despite its name, NgR2 does not bind to Nogo<sup>26</sup>, but it is known to bind to myelin-associated glycoprotein (MAG)<sup>23,25</sup>. Members of the NgR family form a signal transduction complex with the nerve growth factor receptor p75<sup>24,27</sup> and LINGO-1<sup>28</sup> that activates RhoA<sup>29</sup>. RhoA is a member of the Ras superfamily of small GTPases that, in cancer, regulates cytoskeletal dynamics to mediate cell migration<sup>30</sup>. In PrCa, elevated RhoA levels have been associated with aggressive disease and decreased disease-free survival after radical prostatectomy<sup>31</sup>. In addition, enzalutamide-resistant PrCa cells express higher levels of RhoA compared to their enzalutamide-sensitive counterparts<sup>32</sup>. Finally, activation of RhoA by the neuropeptide bombesin stimulates PC3 cell migration<sup>33</sup>.

Here we demonstrate that the  $\alpha\text{V}\beta 3$  integrin, known to be upregulated in NEPrCa<sup>13</sup>, increases the levels of a GPI-anchored receptor called NgR2 (Nogo-66 receptor homolog 1) in NEPrCa cells. The role of the NgR protein family, to the best of our knowledge, has been minimally investigated in cancer<sup>34–36</sup>, as it has been predominantly studied in neurons. Specifically, NgR2 is reported in a correlative study to be associated with Hodgkin lymphoma<sup>34</sup>. We show here that NgR2 is significantly upregulated in NEPrCa patients' tumors and NE cell lines and is co-expressed with NE markers in NEPrCa patient-derived xenografts (PDXs), and different NE mouse models. Moreover, from a mechanistic point of view, we show that NgR2 promotes NE differentiation, anchorage-independent growth, and cell motility. We also show that the  $\alpha\text{V}\beta 3$  integrin immunoprecipitates with NgR2. Finally, the  $\alpha\text{V}\beta 3$  integrin has to be activated by K2 in order to induce NgR2 upregulation. Our results show that NgR2 is a novel effector of the  $\alpha\text{V}\beta 3$  integrin that promotes NED in PrCa and contributes to the highly motile phenotype of NEPrCa.

## Materials and methods

**Cell lines.** Culture conditions for the PrCa cell lines (C4-2B, LNCaP, PC3) have been previously described<sup>4,37,38</sup>. NCI-H660 cells were grown following ATCC instructions. PC3 cells were transfected using lentivirus shRNA clones to: Kindlin-2, clone TRCN0000128058 (which targets a coding sequence of K2); and non-targeting scrambled control SHC002 (purchased from Sigma). The lentivirus-mediated shRNA gene knockdown procedures were previously described in<sup>39,40</sup>. LNCaP cells were used for CRISPR/Cas9-mediated knockout of Kindlin-2 (*FERMT2*) as previously described<sup>41</sup>. Culture conditions for the PrCa cell lines 22Rv1 and VCaP were previously described<sup>42</sup>.

**Generation of Kindlin-2 Knockout cell lines using electroporation.** The sgRNA pool of 3 guide RNAs (G\*A\*C\*GGGAUAAGGAUGCCAGA, C\*G\*C\*GGUUCAGGUCCGUCACA and A\*G\*G\*CGUGAUGCUUAAGCUGG with their respective Synthego modified EZ scaffolds) targeting *FERMT2* and the scramble control were obtained from Synthego. The sgRNA pellets were rehydrated in 1X TE buffer (provided by Synthego) to make a stock of 100  $\mu\text{M}$ . A working solution of 30  $\mu\text{M}$  sgRNA was made (in nuclease free water) fresh before electroporating the cells. For every reaction, the Ribonucleoprotein (RNP) complex was assembled by adding 3  $\mu\text{l}$  of 30  $\mu\text{M}$  sgRNA to 0.5  $\mu\text{l}$  of 20  $\mu\text{M}$  Cas9 (provided by Synthego) at a ratio of 9:1 in 3.5  $\mu\text{l}$  resuspension buffer R (Neon Transfection System; Invitrogen Basel, Switzerland) and incubated for 10 min at room temperature.

Electroporation of LNCaP cells was achieved by an implemented electroporation device system according to manufacturer's instructions (Neon Transfection System; Invitrogen, Basel, Switzerland). The Neon Transfection System 10  $\mu\text{L}$  kit was used for the transfection of human prostate cancer cells. Cells were cultured 48 h before electroporation and harvested at nearly 80% confluency. Cells at a density of  $2 \times 10^5$  were washed with PBS and resuspended in 5  $\mu\text{l}$  resuspension buffer R (Neon Transfection System; Invitrogen Basel, Switzerland). Within 15 min of resuspension, the cells were added to the tube containing RNP and the cell-RNP complex was electroporated with the Neon Transfection System. Per electroporation,  $2 \times 10^5$  cells were taken up in a 10  $\mu\text{l}$  Neon tip using the Neon Transfection System pipette (Invitrogen). The electroporation was performed by applying 3 pulses at 1450 Volts for 10 ms to PC3 cells and 2 pulses at 1200 Volts for 20 ms to LNCaP cells. Control cells were incubated with the resuspension buffer without the sgRNA and electroporated at the same settings. After electroporation, the cells were seeded in a 6-well plate by adding 2.5 ml DMEM (Cytiva) with 10% FBS without antibiotic supplements. The cells were cultured for 48–72 h and subsequently proceeded for further analysis. Western blot analysis was used to assess the Kindlin-2 KO efficiency in all cell lines.

**Antibodies.** The following antibodies (Abs) were used: for the immunoblotting (IB) analysis, rabbit monoclonal Abs against the  $\alpha$ V $\beta$ 3 integrin (13166S, Cell Signaling) and Aurora Kinase A (14475S, Cell Signaling), polyclonal goat Abs against the  $\alpha$ V $\beta$ 6 integrin (AF2389, R&D system) and NgR2 (AF2776, R&D system), rabbit polyclonal Abs against calnexin (CANX, sc11397, Santa Cruz), actin (a2066, Sigma), RhoA (sc-179, Santa Cruz), TSG101 (Abcam, ab30871), mouse monoclonal Abs against RhoA (sc-418, Santa Cruz), NSE (LS-C197136, LSBio), Kindlin-2 (MAB2617, Millipore), were also used. For immunohistochemical analysis, rabbit monoclonal Ab against the  $\beta$ 3 integrin (13166S, Cell Signaling), rabbit polyclonal Abs against SYP (PA1-1043, Invitrogen), and NgR2 (PA5-98577, Invitrogen) were also used. Rabbit IgG (I5006, Sigma) was used as negative control. For immunoprecipitation, rabbit polyclonal Ab against NgR2 (PA5-98577, Invitrogen), rabbit monoclonal Ab against the  $\beta$ 3 integrin (13166S, Cell Signaling), mouse monoclonal Abs against the  $\beta$ 6 (62A1) and  $\beta$ 1 integrins (NBP2-52708, Novus) were used. For the adhesion assay, the  $\alpha$ V $\beta$ 3 integrin (LM609, Millipore MAB1976), and the non-immune mouse IgG (02-6502, Thermo Fisher) were used.

**Immunoprecipitation.** PC3 cells were lysed with lysis buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 1% Triton X-100, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM Na<sub>4</sub>O<sub>7</sub>P<sub>2</sub>, 50 mM NaF, 0.01% aprotinin, 4  $\mu$ g/ml pepstatin, 10  $\mu$ g/ml leupeptin, 1 mM PMSF, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 1  $\mu$ M Calpain inhibitor) and pre-clearing was performed by two consecutive incubations with protein G-Sepharose (17061801, Cytivia) at 4 °C for 30 min. Binding to specific Abs was performed by incubation at 4 °C overnight, followed by incubation with protein G-Sepharose at 4 °C for 3 h. After six washes with lysis buffer, immunocomplexes were resuspended in 1X reducing Laemmli buffer and separated by SDS-PAGE. All western blotting films were developed using the Protec Optimax developer system. The film's images were acquired using a Microtek ArtixScan M2 and processed using the Microtek Scan Wizard Pro V8.20 software.

**PrCa cell transfection.** PC3 cells were transfected with three different shRNA constructs that target *RTN4RL2* (SMARTvector, Dharmacon/Horizon, SO-2914049G, sequences: V3SVHS00\_4716901 for shRTN4RL2\_1, and V3SVHS00\_8801245 for shRTN4RL2\_3). As a control, PC3 cells were transfected with a non-targeting scrambled control shRNA (SMARTvector, Dharmacon/Horizon, VSC11707). DU145 cells were transfected with pCMV6-Entry vector carrying *RTN4RL2* (Origene, SC310413) or with the empty vector as a control (Origene, PS100001). Cells were plated ( $2.5 \times 10^5$ ) in a 6-well plate and grown overnight at 37 °C. The next day, cells were washed with PBS and incubated with 1 mL serum-free media at 37 °C for 2 h. For transfection, 4  $\mu$ g of plasmid was mixed with 12  $\mu$ L of lipofectamine 2000 (Invitrogen, 11668-019) in 200  $\mu$ L of serum-free RPMI media. The plasmid-lipofectamine mix was incubated at room temperature for 25 min. The mix was then added drop-wise to the cells and incubated at 37 °C for 6 h. After 6 h, 700  $\mu$ L of growth medium (without pen-strep) was added to the cells and incubated at 37 °C overnight. After 24 h, the medium was replaced with the growth medium, and cells were incubated for 48 h at 37 °C. For the selection of the transfected cells, the growth medium was supplemented with puromycin (3  $\mu$ g/mL) for PC3 cells and G418 (0.5 mg/ml) for DU145 cells. The pooled populations of selected cells were maintained in complete media containing 2  $\mu$ g/mL of puromycin for PC3 cells and 0.5 mg/ml of G418 for DU145 cells.

**siRNA transfection.** Downregulation of *RTN4RL2* (NgR2) expression was accomplished using siRNA SMARTPool (L-008045-00-0010, Dharmacon/Horizon). For the downregulation of *ITGB3* FlexiTube (Qia-gen) siRNAs were used. In Fig. 1: siRNA\_2, SI00004599 (target sequence, CTCTCCTGATGTAGCACTTAA), siRNA\_3, SI00004606 (target sequence, CAAGCTGAACCTAATAGCCAT), and siRNA\_4, SI02623159 (target sequence, CACGTGTGGCCTGTTCTCTA) were used.


Transfection of the siRNA and immunoblotting analysis were performed as previously described<sup>14</sup>. Briefly, 300,000 cells were transfected with siRNA (final concentration 100 nM) duplexes using oligofectamine at a final concentration of 20 nM. Twenty-four hours after transfection, the siRNAs were removed, and the cells were kept in complete media overnight. This process was repeated for a second time, after which the cells were harvested and analyzed.

**RNA sequencing.** The heatmap of gene expression in cell lines was generated using Broad Institute Morpheus software (MA, USA). Statistical analysis was done using GraphPad Prism (CA, USA) and differences between two groups were compared by unpaired student's t-test.

**RNA sequencing of metastatic CRPrCa samples.** RNA sequencing analysis of metastatic CRPrCa specimens acquired through rapid autopsy of 98 patients was performed as previously described<sup>43</sup>. Specimens were classified based on their levels of AR and NE markers. AR-positive and NE-negative (n=76), AR low NE-negative (n=13), AR-positive NE-positive (n=9), AR-negative NE-negative (n=8), and AR-negative NE-positive (n=11).

**Generation of mice carrying prostate-specific deletions.** Mice of genotype PB-Cre4 *pten*<sup>loxP/loxP</sup> *rb1*<sup>loxP/loxP</sup> *trp53*<sup>loxP/loxP</sup> (TKO), and PB-Cre4 *pten*<sup>loxP/loxP</sup> (SKO) were generated as previously described<sup>44</sup>. Mice with the same genetic background (mixed C57BL/6 and 129SVJ) were used for the wild-type control.

**Generation of NgR2 knockout mice.** NgR2-null, and NgR1-null mice have been previously described<sup>45–47</sup>. Wild-type (WT) littermate controls, NgR2<sup>-/-</sup> and NgR1<sup>-/-</sup> animals were obtained by mating heterozygous NgR2<sup>+/-</sup> and NgR1<sup>+/-</sup> animals, respectively.



**Figure 1.** The  $\alpha$ V $\beta$ 3 integrin increases NgR2 expression and is associated with NgR2. **(A)** Immunoblotting analysis of the expression levels of the  $\alpha$ V $\beta$ 3 integrin and NgR2 ( $n = 3$ , left panels), and of the  $\alpha$ V $\beta$ 3 integrin, the NE markers chromogranin A (CHGA) and neuron-specific enolase (NSE;  $n = 1$ , middle panels), in C4-2B cells that exogenously express  $\alpha$ V $\beta$ 3 or their mock control cells. Right panel, immunoblotting analysis of the expression levels of the  $\alpha$ V $\beta$ 3 integrin, and NgR2 in PC3 cells in which the  $\alpha$ V $\beta$ 3 integrin expression was downregulated using three different siRNAs against *ITGB3* (the gene responsible for the  $\beta$ 3 integrin subunit). Non-silencing siRNA (NS) was used as control. Calnexin was used as loading control. **(B)** PC3 cell lysates were immunoprecipitated with Abs against the  $\alpha$ V $\beta$ 3 integrin, NgR2, the  $\beta$ 1 integrin, the  $\alpha$ V $\beta$ 6 integrin or their isotype controls (left panel) and the  $\alpha$ V $\beta$ 3 integrin, NgR2, and the  $\alpha$ V $\beta$ 6 integrin (right panel). Immunoprecipitates were analyzed for NgR2, the  $\beta$ 1 integrin, the  $\alpha$ V $\beta$ 3 integrin, and the  $\alpha$ V $\beta$ 6 integrin by immunoblotting ( $n = 2$ ). Immunoblotting analyses were performed under non-reducing (left panel) and reducing conditions (right panel). NgR2 was detected using two different Abs (left panel).

**Animal care.** Care of animals followed standards established by the Office of Laboratory Animal Welfare, NIH, Department of Health and Human Services. All mice were maintained following the recommendations of the Institutional Animal Care and Use Committee which is a standing committee mandated by Federal law and regulations that ensures the humane and ethical treatment of animals. All experimental protocols were approved by the Animal Care and Use Committees at the institutions where the mice were hosted: Thomas Jefferson University for CB-17 SCID mice; Roswell Park Cancer Center for TKO mice and the Medical University of Innsbruck, Austria for NgR2-null and NgR1-null mice. This study is reported in accordance with ARRIVE guidelines.

**Immunohistochemical analysis.** Immunohistochemical analysis was performed on tissue sections of 5 TKO (primary tumor and lung metastases), and LuCaP PDXs TMA as previously described<sup>13</sup>. The tissue sections were incubated overnight at 4 °C with Abs against the  $\beta$ 3 integrin subunit (1:25), NgR2 (1:500 for mouse samples and 1:1000 for LuCaP PDXs TMA), SYP (1:200), or the IgG isotype, which was used as the negative control. The following day, the tissue sections were washed with PBST (5 min  $\times$  2), followed by PBS (5 min), and incubated with biotinylated goat anti-rabbit IgG (BA-1000, Vector Laboratories) in PBST for 30 min at room temperature. Pictures were acquired using an Olympus BX43 microscope and the imaging processing was performed using the Olympus Sens Entry V2.3 software.

The specificity of our IHC staining was confirmed by staining dorsal root ganglion sections samples from three NgR2 knockout mice (Fig. S1A<sup>45</sup>) or by preincubating for 1 h the NgR2 Ab (Invitrogen, PA5-98577) with the blocking peptide (DSRGRQGDDAPTEDDYWG, 10  $\mu$ g/ml, Thermo Fisher) that is specifically recognized



by this Ab (Fig. S1B). The preincubated Ab was then used for immunostaining of rat brain samples or primary tumors from a NEPrCa patient (Fig. S1B).

**Human subject inclusion criteria.** The NEPrCa tissue sample was obtained from the Department of Pathology at Thomas Jefferson University (Philadelphia, PA). The specimen was de-identified and discarded in accordance with guidelines established by the Institutional Review Board (IRB), an administrative body established to protect the rights and welfare of human research subjects recruited to participate in research activities conducted at Jefferson.

**LuCaP TMA immunohistochemical assessment and statistical analysis.** The immunostaining of each LuCaP was scored as previously reported<sup>13</sup>.

**MTT assay.** PC3 cells treated with oligofectamine, non-silencing siRNA, or siRNA specifically targeting *RTN4RL2* were plated ( $10^4$ ) in 100  $\mu$ L complete media on 96 well plates (six replicates) and analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/mL).

**Boyden chamber assay.** PC3 cells treated with oligofectamine, non-silencing siRNA, or siRNA specifically targeting *RTN4RL2* were seeded ( $5 \times 10^4$ ) on fibronectin-coated (10  $\mu$ g/ml) Transwell chambers (three replicates) in serum-free media and analyzed as been previously described<sup>38</sup>.

**Anchorage-independent growth assay.** Six-well plates were coated with 0.8% agarose to create a bottom layer and 10,000 PC3 cells (parental, scramble, or sh*RTN4RL2*) from each well were resuspended in 2 mL of complete medium (RPMI containing 10% FBS, 100  $\mu$ g/mL streptomycin, and 100 U/mL penicillin). The protocol has been previously described<sup>12</sup>. Pictures were acquired using a Nikon Eclipse TS100 microscope and the imaging processing was performed using the NIS Elements F3.0 software.

**Adhesion assay.** Adhesion assays were performed as previously described<sup>48</sup>.

**$\alpha$ V $\beta$ 3 activation assay.** Activation assays were performed as previously described<sup>49</sup>.


## Results

**The  $\alpha$ V $\beta$ 3 integrin increases NgR2 levels and is associated with NgR2 in PrCa cells.** Our previous studies have shown that  $\alpha$ V $\beta$ 3 expression correlates with NEPrCa phenotype<sup>13</sup>. Therefore, we investigated mechanisms that would be selectively altered by  $\alpha$ V $\beta$ 3 expression. We find that the exogenous expression of the  $\alpha$ V $\beta$ 3 integrin induces a significant increase of NgR2 levels, as well as the NE markers chromogranin A (CHGA) and neuron-specific enolase (NSE) in C4-2B and LNCaP cells (Fig. 1A, left and middle panels, and Fig. S2). Moreover, when the expression levels of the  $\alpha$ V $\beta$ 3 integrin are reduced using siRNA against *ITGB3* (the gene responsible for the  $\alpha$ V $\beta$ 3 integrin) the NgR2 protein levels are reduced as well (Fig. 1, right panel) demonstrating that NgR2 expression is under the control of the  $\alpha$ V $\beta$ 3 integrin. These data suggest that NgR2 is a downstream effector of the  $\alpha$ V $\beta$ 3 integrin that may promote PrCa progression toward a NE phenotype.

In order to investigate if NgR2 interacts with the  $\alpha$ V $\beta$ 3 integrin, we performed immunoprecipitation of NgR2, and the  $\alpha$ V $\beta$ 3,  $\alpha$ V $\beta$ 6, and  $\beta$ 1 integrins in PC3 cells. The immunoblotting analysis shows that NgR2 co-precipitates in a unique manner with the  $\alpha$ V $\beta$ 3 integrin but not with the  $\alpha$ V $\beta$ 6 integrin nor with the  $\beta$ 1 integrins (Fig. 1B). We then conclude that NgR2 may act as a cofactor that would affect  $\alpha$ V $\beta$ 3 function by associating with this integrin.


**The  $\alpha$ V $\beta$ 3/NgR2 pathway is upregulated in human and mouse NEPrCa.** To determine if NgR2 expression is relevant in NEPrCa we compared different prostate cancer cell lines in the Cancer Cell Line Encyclopedia (CCLE) database<sup>50</sup>. NCI-H660, a NEPrCa cell line, expresses high *RTN4RL2* (the gene encoding for NgR2) mRNA levels compared to the AR positive cell lines LNCaP, 22Rv1, and VCaP as well as the AR negative cell lines, DU145 and PC3 (Fig. 2A). The 22Rv1 cell line instead maintains AR as well as *SYP* expression but low levels of *RTN4RL2* (NgR2). The gene for *SYP* (synaptophysin) was used as a NE marker, and the genes for AR and *KLK3* (Kallikrein Related Peptidase 3) were used as markers of the AR activity. Screening of the University of Washington metastasis dataset<sup>43</sup> and classification of the metastatic CRPrCa samples by their expression levels of AR and NE markers shows increased levels of *RTN4RL2* (NgR2) in those samples that have similar characteristics as NEPrCa tumors (ARneg\_NEpos) compared to the AR-positive NE-negative samples, AR low NE-negative samples, AR-positive NE-positive samples, and AR-negative NE-negative samples (Fig. 2B). We then analyzed RNA-seq data for NEPrCa and CRPrCa tumors from cBioportal (dataset Neuroendocrine Prostate Cancer, Multi-Institute<sup>20</sup>) and estimated whether a differential expression between the two groups is observed. The t-test results show a significantly higher expression of *RTN4RL2* (NgR2) in NEPrCa samples compared to the CRPrCa samples (Fig. 2C). In contrast, the other two members of the NgR family (NgR1 and NgR3) do not show differential expression between NEPrCa and CRPrCa that passed correction for multiple testing (FDR < 10% threshold; Fig. S3). In particular, *RTN4RL1* (NgR3) does not exhibit significant differences between the two groups ( $P=0.12$ ), while *RTN4R* (NgR1), although it has significance with a  $P$ -value of 0.008, shows FDR = 12%, compared to NgR2  $P=0.00098$ , FDR = 6%. These results suggest a unique role of NgR2 in the NgR family during cancer progression and metastasis in patients with NEPrCa.

To further support the involvement of NgR2 in NEPrCa, we assessed the presence of NgR2 using immunohistochemical analysis (Fig. 2D) and scored the immunostaining intensity and percentage of cells at each staining



**Figure 2.** NgR2 expression is increased in NEPrCa patients, NE cell lines, and NEPrCa PDXs. (A) Left panel, mRNA levels for *RTN4RL2*, *SYP* (Synaptophysin), *KLK3* (Kallikrein Related Peptidase 3), and *AR* (Androgen Receptor) reported as Transcripts Per Million were compared across multiple PrCa cell lines in the CCLE database<sup>50</sup>. (B) RNA sequencing analysis for *RTN4RL2* of metastatic CRPrCa specimens acquired through rapid autopsy of 98 patients. Specimens are classified based on their levels of AR and NE markers. AR-positive NE-negative (ARpos\_NEneg, n = 76), AR low NE-negative (ARlow\_NEneg, n = 13), AR-positive NE-positive (ARpos\_NEpos, n = 9), AR-negative NE-negative (ARneg\_NEneg, n = 8), and AR-negative NE-positive (ARneg\_NEpos, n = 11). Statistical analysis was performed using GraphPad Prism (CA, USA) and differences between two groups were compared using unpaired student's t-test. (C) RNA sequencing analysis of *RTN4RL2* expression for CRPrCa and NEPrCa tumors from cBioPortal (dataset Neuroendocrine Prostate Cancer, Multi-Institute<sup>20</sup>). Differential expression between the two groups is estimated by student's t-test. (D) Representative IHC staining for the  $\alpha V\beta 3$  integrin or NgR2 of LuCaP PDX TMAs (n = 37) is shown. IgG was used as negative control. The bar at the bottom right corner of each panel represents 20  $\mu m$ . (E) Heat map of the histochemical score for SYP, NgR2, and the  $\alpha V\beta 3$  integrin of each LuCaP is shown. \* $P = 0.029$ ; \*\* $P = 0.003$ . Spearman correlation was performed and r-values are reported. The histochemical score for the  $\alpha V\beta 3$  integrin and SYP has been previously reported<sup>13</sup>.






**Figure 3.** NgR2 expression is increased in NEPrCa TKO mouse tumors. (A, B) Representative immunohistochemical staining of the  $\alpha$ V $\beta$ 3 integrin, NgR2, and SYP of prostate tumors (top row) and lung metastasis (bottom row) from TKO mice (A, n = 5) and of primary tumors from SKO mice (B, n = 5). (C) Representative immunohistochemical staining of NgR2 of prostate samples from wild-type mice (n = 4). IgG was used as negative control (A–C). The bars at the bottom right corner of each panel represent 20  $\mu$ m.

level of 37 LuCaP PDXs<sup>43,51</sup> in the tumor microarrays (TMAs) using the scoring system described in the Materials and Methods section and previously reported<sup>13</sup>. These PDX models were generated by implanting primary PrCa or metastatic lesion tumor fragments from PrCa patients into immunocompromised mice<sup>51</sup>, and the resulting PDX models were subsequently characterized for their expression of NE markers<sup>43</sup>. We previously reported a positive correlation between the  $\alpha$ V $\beta$ 3 integrin and the NE marker, SYP ( $r = 0.420$ ;  $P = 0.0046$ )<sup>13</sup> in these LuCaP PDXs. Our immunohistochemical analysis now shows a positive correlation between NgR2 and the  $\alpha$ V $\beta$ 3 integrin ( $r = 0.360$ ,  $P = 0.029$ ), as well as between NgR2 and the NE marker, SYP ( $r = 0.479$ ,  $P = 0.003$ ) (Fig. 2E).

In addition, we assessed the levels of NgR2 and the  $\alpha$ V $\beta$ 3 integrin in primary tumors and metastatic lung lesions from NEPrCa mice carrying *pten*, *rb1*, and *trp53* triple conditional deletions in the prostatic epithelium (PBCre4 *pten*<sup>loxP/loxP</sup> *rb1*<sup>loxP/loxP</sup> *trp53*<sup>loxP/loxP</sup>, TKO). This model develops NEPrCa similarly to its human counterpart<sup>44</sup>. The immunostaining analysis reveals co-expression of NgR2 and the  $\alpha$ V $\beta$ 3 integrin (Fig. 3A) in SYP-positive TKO tumors. Moreover, we analyzed tumors from a single conditional knockout mouse model (PBCre4 *pten*<sup>loxP/loxP</sup>, SKO) that develops adenocarcinoma tumors of the prostate. NgR2 is still detectable in these tumors (Fig. 3B). These tumors do not express  $\alpha$ V $\beta$ 3 or NE markers, indicating the requirement of both  $\alpha$ V $\beta$ 3 and NgR2 for NED. Finally, we show that NgR2 is undetectable in prostate samples from wild-type mice, known to be  $\alpha$ V $\beta$ 3 negative<sup>13</sup> (Fig. 3C).

These results confirm the presence of NgR2 in human NE tumors and metastases, NEPrCa PDXs, the NEPrCa cell line NCI-H660, and NE tumors of TKO mice, further supporting our hypothesis that NgR2 has a role during PrCa progression toward a NE phenotype and metastasis.

**NgR2 controls NE marker expression and anchorage-independent growth in PrCa cells.** To further investigate the role of NgR2 during cancer progression and in cell motility, we reduced NgR2 expression in NCI-H660 cells (Fig. 4A) and C4-2B cells that exogenously express  $\alpha$ V $\beta$ 3 (Fig. 4B) using a pool of siRNAs (Fig. 4A, B) against *RTN4RL2* (NgR2). Upon NgR2 downregulation, our results show a reduced expression of the NE markers NSE, and SYP, as well as Aurora Kinase A (AURKA, Fig. 4A, B), which has been reported to be upregulated in NEPrCa<sup>42,52</sup>. RhoA, a known motility promoter<sup>53</sup>, and downstream effector of NgRs<sup>54</sup> is also downregulated in both cell lines upon siRNA treatment (Fig. 4A, B left panel). On the other hand, when NgR2 is exogenously expressed in DU145 cells, the NE markers NSE and CHGA levels are upregulated (Fig. 4C). Moreover, RhoA is increased in these cells (Fig. 4C). Noticeably, the  $\alpha$ V $\beta$ 3 integrin is not increased by NgR2, suggesting that NgR2 is a downstream effector of this integrin. Taken together, these results suggest that NgR2 is involved in PrCa progression toward a NE phenotype.




**Figure 4.** NgR2 induces NE markers and RhoA in CRPrCa and NEPrCa cells in vitro. (A) Immunoblotting analysis of the expression levels of the  $\alpha V\beta 3$  integrin (on a 7.5% PAGE), NgR2 and Aurora Kinase A (AURKA, on a 7.5% PAGE), and neuron-specific enolase (NSE) and RhoA on a 12.5% PAGE in NCI-H660 cells in which NgR2 expression was downregulated using a pool of siRNAs against *RTN4RL2* (NgR2). AURKA and NSE protein expression, measured using densitometric analysis, is reduced 11.22 and 8.4 fold, respectively, when compared to the non-silencing siRNA control (n = 4). (B) Left panel, immunoblotting analysis of the expression levels of NgR2 (on a 7.5% PAGE); RhoA and synaptophysin (SYP, on a 10% PAGE) in C4-2B cells that exogenously express  $\alpha V\beta 3$  in which NgR2 expression was downregulated using a pool of siRNA against *RTN4RL2*. Right panel, immunoblotting analysis of the expression levels of the  $\alpha V\beta 3$  integrin, AURKA, and NSE (on a 12.5% PAGE) in C4-2B cells that exogenously express the  $\alpha V\beta 3$  integrin and in which NgR2 expression was downregulated using a pool of siRNAs against *RTN4RL2* (n = 3). AURKA and NSE protein expression, measured using densitometric analysis, is reduced 3.59 and 3.9 fold, respectively, when compared to the non-silencing siRNA control. (A,B) –, Oligofectamine; NS, non-silencing. (C) Immunoblotting analysis of the expression levels of NgR2 (on a 10% PAGE), the  $\alpha V\beta 3$  integrin, NSE, and RhoA (on a 10% PAGE), and Chromogranin A (CHGA, on a 10% PAGE) in DU145 cells that exogenously express NgR2 or their mock control cells (n = 2). Actin or CANX was used as loading control (A–C). All immunoblotting analyses were performed under reducing conditions.


Next, we investigated the effects of NgR2 on anchorage-independent growth of PrCa cells. We stably knocked down NgR2 expression in PC3 cells using shRNA (Fig. 5A) and evaluated their anchorage-independent growth. As a control, we used scrambled shRNA transfected cells. In these cells, we do not detect significant differences in the expression levels of the  $\alpha V\beta 3$  integrin (Fig. 5A). The reduced expression of NgR2 results in a significant decrease of PC3 colony size (Fig. 5B), showing that NgR2 promotes anchorage-independent growth of PrCa cells. Moreover, we downregulated NgR2 using siRNA in PC3 cells and used these cells to analyze whether NgR2 affects cell proliferation and motility. As control, we used non-silencing RNA transfected cells. Our proliferation assay shows no significant differences upon reduced NgR2 expression (Fig. 6A). On the other hand, the motility of PC3 cells upon knockdown of NgR2 expression is significantly reduced (Fig. 6B). These results show that NgR2 promotes anchorage-independent growth and motility rather than the proliferation of PrCa cells, suggesting a potential role in metastasis formation.

Suppression of the  $\alpha V\beta 3$  integrin activation by Kindlin-2 downregulation reduces NgR2 expression levels.


We then assessed whether increased expression of NgR2 requires the  $\alpha V\beta 3$  integrin to be in an activated state (high affinity/avidity for ligand). In order to de-activate the  $\alpha V\beta 3$  integrin, we downregulated the expression of the integrin co-activator K2 in PC3 and in LNCaP cells using shRNA or sgRNA, respectively (Fig. 7A and Fig. S4A). Our results show that NgR2 levels were reduced by K2 downregulation (Fig. 7A and Fig. S4A). We confirmed that when inactivation of the  $\alpha V\beta 3$  integrin activity is reduced by K2 downregulation, NgR2 levels are decreased as well. We confirmed the reduced activation of the  $\alpha V\beta 3$  integrin by assaying the ability of the PC3 cells to bind Fibrinogen (Fg) by flow cytometry and adhesion assay. When K2 expression levels were



**Figure 5.** NgR2 increases the anchorage-independent growth of PC3 PrCa cells. **(A)** Immunoblotting analysis of the  $\alpha V\beta 3$  integrin, and NgR2 expression levels in different PC3 cell transfectants in which NgR2 is downregulated using shRNA against *RTN4RL2* (NgR2). CANX was used as loading control. The immunoblotting analysis was performed under reducing conditions. **(B)** Left panels, representative images of the colonies formed by the PC3 cells containing shRNA against *RTN4RL2* (NgR2), the scramble shRNA control, and the parental cells. Right panel, average colony area of the PC3 cells shown in **(A)** grown in 0.3% agar as described in the Materials and Methods section. Each condition has been replicated three times, and a total of nine fields per condition has been recorded. Values are reported as mean  $\pm$  SEM. Significance was calculated by student's t-test.



**Figure 6.** NgR2 modulates the motility but not the proliferation of PrCa cells. **(A)** PC3 cells, in which NgR2 expression was downregulated using a pool of siRNAs against *RTN4RL2* (NgR2), were plated on 96-well plates ( $1 \times 10^4$ ,  $n = 6$ ) in complete media. After 24 h, the viability of PC3 cells was determined by MTT assay; values are reported as mean  $\pm$  SEM. **(B)** The PC3 cells were also plated ( $5 \times 10^4$ ,  $n = 3$ ) on fibronectin-coated (10  $\mu\text{g}/\text{ml}$ ) Transwell chambers in serum-free media in both top and bottom chambers as previously described<sup>4</sup>. The dot plot represents the number of PC3 cells migrated in each treatment group towards the bottom chambers in 6 h (9 fields for each condition, field of view = 0.055 mm diameter). Values are reported as mean  $\pm$  SEM;  $P$ -values were calculated by unpaired t-test using GraphPad Prism. OF, Oligofectamine; NS, non-silencing; n.s., non-significant.



**Figure 7.** The αVβ3 integrin must be active to induce Ngr2 in PrCa cells. (A) Immunoblotting analysis of the expression levels of Kindlin-2, Ngr2, αVβ3, and RhoA in the lysates from PC3 cells in which Kindlin-2 expression was downregulated using shRNA targeting FERMT2 (the gene responsible for Kindlin-2). CANX was used as loading control. (B) Flow cytometry analysis of αVβ3 activation by its capacity to bind soluble Fg-Alexa Fluor 488 in PC3 cells transfected with a shRNA against FERMT2 or the non-targeting shRNA control (n = 2). Values are reported as Mean Fluorescence Intensity (MFI), and P-values were calculated by unpaired t-test using GraphPad Prism. (C) Immunoblotting analysis of the expression levels of the αVβ3 integrin and Kindlin-2 in C4-2B cells that express the αVβ3 integrin or their mock control. Actin was used as loading control. All immunoblotting analyses were performed under reducing conditions. n.s., non-significant; \*\*\*P < 0.001.

reduced by shRNA, the capacity of αVβ3 to specifically bind Fg was ablated (Fig. 7B and Fig. S4B). This binding is confirmed to be specific since Fg binding is inhibited by the function-blocking αVβ3 antibody LM609 (Fig. 7B and Fig. S4B). Our results confirm reduced PC3 cell binding in the absence of K2 due to the reduced αVβ3 integrin activity (Fig. 7B and Fig. S4B). In addition, we were able to bypass the inactivation of the αVβ3 integrin by incubating the K2 downregulated PC3 cells with Mn<sup>2+</sup> (Fig. 7B) which has been reported to activate the αVβ3 integrin independently from K2 and inside-out signaling<sup>55</sup>.


## Discussion

In this study, we demonstrate that the αVβ3 integrin activates a signaling pathway in cancer cells that requires the expression of a GPI-linked surface molecule, Ngr2, also known as Nogo-66 receptor homolog 1. We show here that Ngr2 promotes NED, tumor growth, as well as a motile phenotype of PrCa cells; these findings are novel because Ngr2 has minimally been investigated in cancer<sup>34</sup> and has instead been predominantly analyzed in neuroscience studies.

Here we show that Ngr2 levels are increased upon αVβ3 integrin expression and Ngr2 co-precipitates with the αVβ3 integrin. To the best of our knowledge, this is the first time that an interaction between Ngr2 and any integrin has been reported. We envision that an association between Ngr2 and the αVβ3 integrin, shown in this study, may form a pro-tumorigenic and pro-metastatic complex in PrCa cells. Similar associations have been shown for members of the Ngr family; when they bind to MAG, they form a signal transduction complex with the nerve growth factor receptor (NGFR) p75<sup>24,27</sup>. This receptor is known to drive phenotype switching in melanoma<sup>56</sup> and has been recently demonstrated to promote melanoma metastasis when released in extracellular vesicles<sup>57</sup>. Similarly, Ngr2 might stimulate an aggressive phenotype in PrCa through p75 in a complex with the αVβ3 integrin. We thus speculate that neuronal vesicular Ngr2 may also contribute to cancer cell invasion; by co-opting a mechanism used by nerves, which promotes neural invasion of cancer cells in a paracrine manner<sup>58</sup>, Ngr2 may be taken up by cancer cells, associate with the αVβ3 integrin and promote PrCa progression. Finally, cellular context may affect Ngr2 association with the αVβ3 integrin since previous studies have shown that Ngr2 binding to either MAG or to a proteoglycan, versican, inhibits the functions of adult neurons<sup>46,59</sup> or stimulates activities in the neurons of newborns<sup>60,61</sup>.

We show that Ngr2 regulates NE marker expression in PrCa cells, indicating the involvement of Ngr2 in NED. Based on these results showing that αVβ3 integrin and Ngr2 drive NED in PrCa and increased motility of NEPrCa and on the fact that the αVβ3 integrin and Ngr2 are surface receptors and therefore easily targetable, they are suitable for novel therapeutic approaches in this disease. This approach is in line with a previous study that has shown that the inhibition of the αV integrins by Abituzumab causes the downregulation of several pro-metastatic phenotypes of PrCa cells<sup>62</sup>. However, to prevent the side effects of targeting the αVβ3 integrin, which is expressed in endothelial cells<sup>63,64</sup>, it will be safer to target Ngr2, which is downstream of the αVβ3 integrin and of its co-activator, K2. When the expression levels of Ngr2 in PC3 cells are reduced using shRNA, we do not detect significant differences in the expression levels of the αVβ3 integrin and K2. On the other hand, exogenous expression of Ngr2 does not affect the αVβ3 integrin levels. Overall, these results indicate that Ngr2





**Figure 8.** Schematic representation of the pathway described in this paper. **(A)** The  $\alpha V\beta 3$  integrin, together with its co-activator K2, induces increased levels of NgR2 expression in castrate-resistant prostate cancer cells. In turn, NgR2 regulates the levels of NE markers and stimulates anchorage-independent growth of these cells. NgR2 also upregulates the levels of RhoA that causes increased PrCa cell motility. These cells with increased NgR2 expression are likely to be NEPrCa cells. **(B)** The schematic drawing summarizes our proposed model.

acts downstream of the  $\alpha V\beta 3$  integrin and its co-activator K2 and delineate the molecular sequence of this novel pathway, as summarized in Fig. 8.

We also present evidence that RhoA levels are under the control of NgR2; these results are likely to explain the decreased motility of PrCa cells observed upon NgR2 downregulation. This finding is not surprising since members of the NgR family are known to promote RhoA activation<sup>29</sup> and expression<sup>65</sup>. Furthermore, higher levels of RhoA are found in therapy-resistant PrCa cells<sup>32</sup>, and increased expression and activity of RhoA are essential for invasion and motility of PC3 cells as compared with low invasive PC3 cells<sup>53</sup>. An additional finding is that increased expression of NgR2 and consequently of RhoA requires the  $\alpha V\beta 3$  integrin to be in an activated state (high affinity/avidity for ligand).

Taken together, our results showing that NgR2 does not affect cell viability, but promotes tumor growth and cell motility, collectively reveal and substantiate a remarkable role for NgR2 in regulating the NE phenotype of PrCa cells. Our findings appear to be highly relevant to NEPrCa given our previous observations that high levels of the  $\alpha V\beta 3$  integrin<sup>13</sup> and, as shown here, NgR2 are detected in NEPrCa patients' tumors as well as in TKO mouse tumors. Furthermore, we expect that NgR2 effect will be highly specific, as compared to the other two members of the NgR family, highlighting the importance of NgR2 in NEPrCa. Finally, it should be stressed that NgR2 is detectable in prostate tumors from the SKO mouse model. Tumors from this model do not express the  $\alpha V\beta 3$  integrin or the NE marker SYP; therefore, we speculate that both factors, the  $\alpha V\beta 3$  integrin and NgR2, have to be expressed in order to induce a NE phenotype.

In conclusion, we have identified a novel key mechanism whereby the  $\alpha V\beta 3$  integrin, and its downstream effector, NgR2, promote a NE and motile phenotype in PrCa (Fig. 8). This study paves new avenues toward reaching a comprehensive mechanistic understanding of integrin-directed signaling during PrCa progression toward a NE phenotype and opens new possibilities for therapeutic strategies and/or risk stratification of PrCa patients.

Received: 27 December 2021; Accepted: 30 September 2022

Published online: 07 November 2022

## References

1. Su, C. Y. *et al.* The biological functions and clinical applications of integrins in cancers. *Front. Pharmacol.* **11**, 579068. <https://doi.org/10.3389/fphar.2020.579068> (2020).
2. Ludwig, B. S., Kessler, H., Kossatz, S. & Reuning, U. RGD-binding integrins revisited: How recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field. *Cancers (Basel)* <https://doi.org/10.3390/cancers13071711> (2021).
3. Desgrosellier, J. S. & Cheresch, D. A. Integrins in cancer: Biological implications and therapeutic opportunities. *Nat. Rev. Cancer* **10**, 9–22. <https://doi.org/10.1038/nrc2748> (2010).
4. Zheng, D. Q., Woodard, A. S., Fornaro, M., Tallini, G. & Languino, L. R. Prostatic carcinoma cell migration via  $\alpha V\beta 3$  integrin is modulated by a focal adhesion kinase pathway. *Cancer Res.* **59**, 1655–1664 (1999).
5. Montanez, E. *et al.* Kindlin-2 controls bidirectional signaling of integrins. *Genes Dev.* **22**, 1325–1330. <https://doi.org/10.1101/gad.469408> (2008).



6. Ye, F. *et al.* The mechanism of kindlin-mediated activation of integrin  $\alpha$ IIb $\beta$ 3. *Curr. Biol.* **23**, 2288–2295. <https://doi.org/10.1016/j.cub.2013.09.050> (2013).
7. Theodosiou, M. *et al.* Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin. *Elife* **5**, e10130. <https://doi.org/10.7554/eLife.10130> (2016).
8. Bledzka, K. *et al.* Tyrosine phosphorylation of integrin  $\beta$ 3 regulates kindlin-2 binding and integrin activation. *J. Biol. Chem.* **285**, 30370–30374. <https://doi.org/10.1074/jbc.C110.134247> (2010).
9. Ma, Y. Q., Qin, J., Wu, C. & Plow, E. F. Kindlin-2 (Mig-2): A co-activator of  $\beta$ 3 integrins. *J. Cell Biol.* **181**, 439–446. <https://doi.org/10.1083/jcb.200710196> (2008).
10. Bledzka, K. *et al.* Spatial coordination of kindlin-2 with talin head domain in interaction with integrin  $\beta$  cytoplasmic tails. *J. Biol. Chem.* **287**, 24585–24594. <https://doi.org/10.1074/jbc.M111.336743> (2012).
11. Tu, Y., Wu, S., Shi, X., Chen, K. & Wu, C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. *Cell* **113**, 37–47. [https://doi.org/10.1016/S0092-8674\(03\)00163-6](https://doi.org/10.1016/S0092-8674(03)00163-6) (2003).
12. Quaglia, F. *et al.* Small extracellular vesicles modulated by  $\alpha$ V $\beta$ 3 integrin induce neuroendocrine differentiation in recipient cancer cells. *J. Extracell. Vesicles* **9**, 1761072. <https://doi.org/10.1080/20013078.2020.1761072> (2020).
13. Quaglia, F. *et al.* Differential expression of  $\alpha$ V $\beta$ 3 and  $\alpha$ V $\beta$ 6 integrins in prostate cancer progression. *PLoS ONE* **16**, e0244985. <https://doi.org/10.1371/journal.pone.0244985> (2021).
14. Lu, H. *et al.*  $\alpha$ V $\beta$ 6 integrin promotes castrate-resistant prostate cancer through JNK1-mediated activation of androgen receptor. *Cancer Res.* **76**, 5163–5174. <https://doi.org/10.1158/0008-5472.CAN-16-0543> (2016).
15. Beltran, H. *et al.* The role of lineage plasticity in prostate cancer therapy resistance. *Clin. Cancer Res.* **25**, 6916–6924. <https://doi.org/10.1158/1078-0432.CCR-19-1423> (2019).
16. Abida, W. *et al.* Genomic correlates of clinical outcome in advanced prostate cancer. *Proc. Natl. Acad. Sci. USA* **116**, 11428–11436. <https://doi.org/10.1073/pnas.1902651116> (2019).
17. Aggarwal, R. *et al.* Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. *J. Clin. Oncol.* **36**, 2492–2503. <https://doi.org/10.1200/jco.2017.77.6880> (2018).
18. Beltran, H. *et al.* Aggressive variants of castration resistant prostate cancer. *Clin. Cancer Res.* **20**, 2846–2850. <https://doi.org/10.1158/1078-0432.Ccr-13-3309> (2014).
19. Parimi, V., Goyal, R., Poropatich, K. & Yang, X. J. Neuroendocrine differentiation of prostate cancer: A review. *Am. J. Clin. Exp. Urol.* **2**, 273–285 (2014).
20. Beltran, H. *et al.* Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nat. Med.* **22**, 298–305. <https://doi.org/10.1038/nm.4045> (2016).
21. Kim, J. & Logothetis, C. J. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. *Urol. Clin. N. Am.* **26**, 281–290. [https://doi.org/10.1016/S0094-0143\(05\)70068-9](https://doi.org/10.1016/S0094-0143(05)70068-9) (1999).
22. Brennen, W. N. *et al.* Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. *JCI Insight* **6**, e146827. <https://doi.org/10.1172/jci.insight.146827> (2021).
23. Robak, L. A. *et al.* Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: Development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. *J. Neurosci.* **29**, 5768–5783. <https://doi.org/10.1523/JNEUROSCI.4935-08.2009> (2009).
24. Pignot, V. *et al.* Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor. *J. Neurochem.* **85**, 717–728. <https://doi.org/10.1046/j.1471-4159.2003.01710.x> (2003).
25. Semavina, M. *et al.* Crystal structure of the Nogo-receptor-2. *Protein Sci.* **20**, 684–689. <https://doi.org/10.1002/pro.597> (2011).
26. Barton, W. A. *et al.* Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. *Embo J.* **22**, 3291–3302. <https://doi.org/10.1093/emboj/cdg325> (2003).
27. Wang, K. C., Kim, J. A., Sivasankaran, R., Segal, R. & He, Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. *Nature* **420**, 74–78. <https://doi.org/10.1038/nature01176> (2002).
28. Mi, S. *et al.* LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. *Nat. Neurosci.* **7**, 221–228. <https://doi.org/10.1038/nn1188> (2004).
29. David, S., Fry, E. J. & Lopez-Vales, R. Novel roles for Nogo receptor in inflammation and disease. *Trends Neurosci.* **31**, 221–226. <https://doi.org/10.1016/j.tins.2008.02.002> (2008).
30. Svensmark, J. H. & Brakebusch, C. Rho GTPases in cancer: Friend or foe?. *Oncogene* **38**, 7447–7456. <https://doi.org/10.1038/s41388-019-0963-7> (2019).
31. Schmidt, L. J. *et al.* RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. *Mol. Endocrinol.* **26**, 716–735. <https://doi.org/10.1210/me.2011-1130> (2012).
32. Chen, X. *et al.* Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. *Prostate* **80**, 256–266. <https://doi.org/10.1002/pros.23939> (2020).
33. Zheng, R. *et al.* Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. *Oncogene* **25**, 5942–5952. <https://doi.org/10.1038/sj.onc.1209586> (2006).
34. Osman, Y. *et al.* Functional multigenic variations associated with hodgkin lymphoma. *Int. J. Lab. Hematol.* **43**, 1472–1482. <https://doi.org/10.1111/ijlh.13644> (2021).
35. He, J. Y. *et al.* Overexpression of Nogo receptor 3 (NgR3) correlates with poor prognosis and contributes to the migration of epithelial cells of nasopharyngeal carcinoma patients. *J. Mol. Med. (Berl)* **96**, 265–279. <https://doi.org/10.1007/s00109-017-1618-1> (2018).
36. Hong, J. H. *et al.* Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. *Brain* **144**, 636–654. <https://doi.org/10.1093/brain/awaa408> (2021).
37. Krishn, S. R. *et al.* Prostate cancer sheds the  $\alpha$ v $\beta$ 3 integrin in vivo through exosomes. *Matrix Biol.* **77**, 41–57. <https://doi.org/10.1016/j.matbio.2018.08.004> (2019).
38. Krishn, S. R. *et al.* The  $\alpha$ V $\beta$ 6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis. *J. Extracell. Vesicles* **9**, 1763594. <https://doi.org/10.1080/20013078.2020.1763594> (2020).
39. Taylor, M. A. *et al.* Upregulated WAVE3 expression is essential for TGF- $\beta$ -mediated EMT and metastasis of triple-negative breast cancer cells. *Breast Cancer Res. Treat.* **142**, 341–353. <https://doi.org/10.1007/s10549-013-2753-1> (2013).
40. Sossey-Alaoui, K., Pluskota, E., Szpak, D. & Plow, E. F. The Kindlin2-p53-SerpinB2 signaling axis is required for cellular senescence in breast cancer. *Cell Death Dis.* **10**, 539. <https://doi.org/10.1038/s41419-019-1774-z> (2019).
41. Sossey-Alaoui, K. *et al.* Kindlin-2 regulates the growth of breast cancer tumors by activating CSF-1-mediated macrophage infiltration. *Cancer Res.* **77**, 5129–5141. <https://doi.org/10.1158/0008-5472.Can-16-2337> (2017).
42. Beltran, H. *et al.* Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. *Cancer Discov.* **1**, 487–495. <https://doi.org/10.1158/2159-8290.Cd-11-0130> (2011).
43. Labrecque, M. P. *et al.* Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. *J. Clin. Invest.* **129**, 4492–4505. <https://doi.org/10.1172/JCI128212> (2019).
44. Ku, S. Y. *et al.* Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Science* **355**, 78–83. <https://doi.org/10.1126/science.aah4199> (2017).
45. Wörter, V. *et al.* Inhibitory activity of myelin-associated glycoprotein on sensory neurons is largely independent of NgR1 and NgR2 and resides within Ig-Like domains 4 and 5. *PLoS ONE* **4**, e5218. <https://doi.org/10.1371/journal.pone.0005218> (2009).

46. Bäumer, B. E. *et al.* Nogo receptor homolog NgR2 expressed in sensory DRG neurons controls epidermal innervation by interaction with Versican. *J. Neurosci.* **34**, 1633–1646. <https://doi.org/10.1523/jneurosci.3094-13.2014> (2014).
47. Zheng, B. *et al.* Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. *Proc. Natl. Acad. Sci. USA* **102**, 1205–1210. <https://doi.org/10.1073/pnas.0409026102> (2005).
48. Soloviev, D. A., Pluskota, E. & Plow, E. F. Cell adhesion and migration assays. *Methods Mol. Med.* **129**, 267–278. <https://doi.org/10.1385/1-59745-213-0:267> (2006).
49. Pluskota, E. *et al.* The integrin coactivator kindlin-2 plays a critical role in angiogenesis in mice and zebrafish. *Blood* **117**, 4978–4987. <https://doi.org/10.1182/blood-2010-11-321182> (2011).
50. Ghandi, M. *et al.* Next-generation characterization of the cancer cell line encyclopedia. *Nature* **569**, 503–508. <https://doi.org/10.1038/s41586-019-1186-3> (2019).
51. Nguyen, H. M. *et al.* LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. *Prostate* **77**, 654–671. <https://doi.org/10.1002/pros.23313> (2017).
52. Mosquera, J. M. *et al.* Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. *Neoplasia* **15**, 1–10. <https://doi.org/10.1593/neo.121550> (2013).
53. Hodge, J. C., Bub, J., Kaul, S., Kajdacsy-Balla, A. & Lindholm, P. F. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. *Cancer Res.* **63**, 1359–1364 (2003).
54. Dubreuil, C. I., Winton, M. J. & McKerracher, L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. *J. Cell Biol.* **162**, 233–243. <https://doi.org/10.1083/jcb.200301080> (2003).
55. Bledzka, K. *et al.* Kindlin-2 directly binds actin and regulates integrin outside-in signaling. *J. Cell Biol.* **213**, 97–108. <https://doi.org/10.1083/jcb.201501006> (2016).
56. Restivo, G. *et al.* The low neurotrophin receptor CD271 regulates phenotype switching in melanoma. *Nat. Commun.* **8**, 1988. <https://doi.org/10.1038/s41467-017-01573-6> (2017).
57. Garcia-Silva, S. *et al.* Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. *Nat. Cancer* **2**, 1387–1405. <https://doi.org/10.1038/s43018-021-00272-y> (2021).
58. Gil, Z. *et al.* Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. *J. Natl. Cancer Inst.* **102**, 107–118. <https://doi.org/10.1093/jnci/djp456> (2010).
59. Venkatesh, K. *et al.* The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. *J. Neurosci.* **25**, 808–822. <https://doi.org/10.1523/JNEUROSCI.4464-04.2005> (2005).
60. DeBellard, M. E., Tang, S., Mukhopadhyay, G., Shen, Y. J. & Filbin, M. T. Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein. *Mol. Cell Neurosci.* **7**, 89–101. <https://doi.org/10.1006/mcne.1996.0007> (1996).
61. Mukhopadhyay, G., Doherty, P., Walsh, F. S., Crocker, P. R. & Filbin, M. T. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. *Neuron* **13**, 757–767. [https://doi.org/10.1016/0896-6273\(94\)90042-6](https://doi.org/10.1016/0896-6273(94)90042-6) (1994).
62. Jiang, Y., Dai, J., Yao, Z., Shelley, G. & Keller, E. T. Abituzumab targeting of  $\alpha$ V-class integrins inhibits prostate cancer progression. *Mol. Cancer Res.* **15**, 875–883. <https://doi.org/10.1158/1541-7786.Mcr-16-0447> (2017).
63. Gasparini, G. *et al.* Vascular integrin  $\alpha$ (v) $\beta$ 3: A new prognostic indicator in breast cancer. *Clin. Cancer Res.* **4**, 2625–2634 (1998).
64. Hodivala-Dilke, K. M. *et al.* Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. *J. Clin. Invest.* **103**, 229–238. <https://doi.org/10.1172/jci5487> (1999).
65. Guo, X. & Liu, X. Nogo receptor knockdown and ciliary neurotrophic factor attenuate diabetic retinopathy in streptozotocin-induced diabetic rats. *Mol. Med. Rep.* **16**, 2030–2036. <https://doi.org/10.3892/mmr.2017.6850> (2017).

# Acknowledgements

The authors would like to thank Dr. Mark Fortini and Jennifer Wilson for editing comments; Amir Yarmahmoodi for his support with the NTA. The authors would also like to thank Dr. David Garlick for their insights on NgR2 immunohistochemical staining. Dr. Lorraine Iacovitti and Dr. Eric Kostuk for the rat brain tissue sections used in the experiments shown in Fig. S1B. We thank Veronica Robles for administrative assistance with the preparation of the manuscript.

# Author contributions

F.Q. and L.R.L. conceptualized the study, designed experiments, analyzed the results, and drew conclusions. F.Q. performed most of the experiments. S.R.K. performed the experiments and analyzed the data reported in Fig. 6, wrote RhoA part in introduction, wrote materials and methods section for PrCa cells transfection of shNgR2, MTT assays, and Bowden chamber assays. K.S.A. and E.F.P. provided reagents and reviewed the manuscript; P.S.R. and E.F.P. designed, performed, and analyzed cell adhesion and integrin activation assays, and participated in the writing of the Methods and in the discussion of the data. P.H.P. performed the immunoblotting analysis reported in Fig. 1A. C.D.S. performed the immunoblotting analysis reported in Fig. S4A. S.L. helped with the characterization of the cells shown in Fig. 4C. P.M.C. reviewed the pathological features of the specimens used and analyzed the immunohistochemical data. A.V.K. performed the bioinformatic and statistical analysis shown in Fig. 2. S.Y.K. and H.B. performed the dataset screening reported in Fig. 2A,C. E.C. provided RNA seq data reported in Fig. 2B. M.K. and C.B. provided the images shown in Fig S1A. Q.L. performed the statistical analysis of anchorage-independent growth shown in Fig. 5. F.Q., L.R.L., E.F.P., W.K.K., S.K.R., and D.C.A. discussed all results. F.Q. and L.R.L. wrote the manuscript. All authors provided insights regarding the results and conclusions of the study and reviewed the paper.

# Funding

This study was supported by R01 CA224769 to LRL and NCI P01 CA140043 to LRL and DCA. FQ was supported by the Prostate Cancer Foundation Young investigator award 2021. LRL and FQ were also supported by Philadelphia Prostate Cancer Biome Project. WKK is the PI of the Philadelphia Prostate Cancer Biome Funds. The research reported in this publication utilized the shared flow cytometry facility at the Sidney Kimmel Cancer Center (Thomas Jefferson University, Philadelphia, PA) that the NCI supports under award number P30CA056036. KSA and PSR were supported by a startup fund from MetroHealth System. AVK was supported by NCI R50 CA211199. EFP and EP were supported by 2R01 HL096062 (NHLBI/NIH). EC was supported by NCI P01 CA163227. The maintenance and characterization of the LuCaP PDX models were supported by the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the Department of Defense Prostate Cancer Biorepository

Network (W81XWH-14-2-0183), NCI P01 CA163227. HB is supported by the National Cancer Institute (R37 CA241486-01A1) and the Department of Defense (W81XWH-17-1-0653). DWG is supported by National Cancer Institute grants R01 CA234162 and R01 CA207757. MK and CB were supported by the Austrian Research Foundation (FWF grant DK W1206).

### Competing interests

HB has served as consultant/advisory board member for Janssen, Sanofi Genzyme, Astellas, Astra Zeneca, Merck, Pfizer, Foundation Medicine, Blue Earth, and has received research funding from Janssen Oncology (Inst), AbbVie/Stemcentrx (Inst), Eli Lilly (Inst), Millennium Pharmaceuticals (Inst). DWG has a sponsored research agreement with Celgene/BMS. EC received research funding from, Janssen Research and Development, Bayer Pharmaceuticals, KronosBio, Forma Pharmaceuticals Foghorn, Gilead, Sanofi, AbbVie, and GSK (all Inst.). All other authors have declared that no relevant conflict of interest exists.

### Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-21711-5>.

**Correspondence** and requests for materials should be addressed to L.R.L.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022